<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
	<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
	<title>Pharmacology</title>
	<meta name='Generator' content='Zim 0.73.1'>
	<style type='text/css'>
		a          { text-decoration: none      }
		a:hover    { text-decoration: underline }
		a:active   { text-decoration: underline }
		strike     { color: grey                }
		u          { text-decoration: none;
					 background-color: yellow   }
		tt         { color: #2e3436;            }
		pre        { color: #2e3436;
					 margin-left: 20px          }
		h1         { text-decoration: underline;
					 color: #4e9a06; margin-bottom: 0 }
		h2         { color: #4e9a06; margin-bottom: 0 }
		h3         { color: #4e9a06; margin-bottom: 0 }
		h4         { color: #4e9a06; margin-bottom: 0 }
		h5         { color: #4e9a06; margin-bottom: 0 }
		p          { margin-top: 0              }
		span.zim-tag {
			color: #ce5c00;
		}
		div.zim-object {
			border-style:solid;
			border-width:1px;
		}
		.checked-box {list-style-image: url(data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAABgAAAAYCAYAAADgdz34AAAAAXNSR0IArs4c6QAAAAZiS0dEAP8A/wD/oL2nkwAAAAlwSFlzAAANOgAADMQBiN+4gQAAAAd0SU1FB9gKGQ8sMEGsKGkAAAAZdEVYdENvbW1lbnQAQ3JlYXRlZCB3aXRoIEdJTVBXgQ4XAAAEBUlEQVRIx62V22tdRRTGf7Nn73P2ybntnNOe3NqkPTGgLTVUUZF6QatSLOKTPgqCIqLgQ0H/A1sQQbBYCBb1QfAxiC8tSO1FqHkwJVKtjdTGNraUmObsc9nXmfGh7cGYpM1D5nHWzPetteZb3wg2eB2YqYm4zSadsMtoboiNBH/3TE0awx6j+MRoxoTg/IYRvP19TQrJS0bzhdHGSyKFkLTtjSKwMjyiEz43ynhtP6bdjBCWyFobAf7eT7VhNF/q1FRbjYjmUohlCVPwnB+6FUxMTJipqSmUUhhjEGKd3bMT4ks/Y6oLBK2Yth8hHYtCJXOix7Nf7xLMzc0xOzvLzp078TyPNE3viW3QJPXzhNWbxFFKHCmMhoLn/FHodd48vGfhapdAacXQlkFK5dL6wIUm6fuTZPuvqDQhaMUYYyiVyuQr6rXDexYuAdi3tSv1ZJNs/R/CaszzT+1na88uXFnCEnJVgivBNN8uTJKmHQI/ptOOcXNZzMz9mOqFs90OHpipWcYwlo5P4ebnuOkrvr5wgrH+h3im7y36MzuwRXYZeKha/OhP0EkadFoxQSdGSotedR/+XwMc2XvKdNUFOFqZx6LKZWIiwjgkikNmLp/hm8sH+K1zjFTHXfBYdTi+eJArzXM0GxFxoBDCopLvo/fqEwi1XPkWkGqjFo2TgB1jOYZUKZTS/D1/ncmLh7jon0IbRWoiTi59ymzzJEEQE3cStNZsGxqlfPE57MBbOR8fP3hDGalOO9fq2DlBvmZw8xa2IxACGn6TydlD/O6f5OzSV/zif0cYhLQaEXGkKBbz7Ov/AOlXV1cxgBJRI3fuSTrpTawt18kWIZN1CFuaONI0w0WOXfsI43YIggh/KUSlhqxrMz74AkOZcWBm9QkH+Gw8NDLuITi+m0yzhluSyJzBLcpblUhFxywSRAEtPwQjsKVN30CNh0uvYuOubSHLtN3J0TO1j0pmBNuFbFWRK0gyPRZpktL2I5JQkclKakNlnh54g6ocvevUr/Ai2a7wineEkcJupA3S1Wg0nVZM2E6wbEF5U5G9Q++wI7sfR7h3N8HVNstykBfzH+KJEZwiWD0aIwxCgJ0R1Mu7GXOeJSuK93bZtQIle4D9pUNU5DC5jEsu55AvZakM5NicGyEj8uuz8bUCQgj67QfY671P3vEoeC69gy695U1U7NG7XV0pUwBjDJa1/JJlWWxzHuflzQe5FJ/GsgUVuZ2t8lEkTvfc0aNHb72flBhjVicQQqCUuvM3/M+WDVguWBrMVdDXEGZlBVEUrVCU9d9s5+fnaTQa2PZyPxEIhJaI1EEoZwX4ncynp6fXrmB4eJjR0VFarRbNZnP9P9rt9gohqNVq1Ov1ZbF/AZGev3hLJ2/zAAAAAElFTkSuQmCC)}
		.xchecked-box {list-style-image: url(data:image/png;base64,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)}
		.unchecked-box {list-style-image: url(data:image/png;base64,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)}
		.migrated-box {list-style-image: url(data:image/png;base64,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)}
		ul {list-style-image: none}
		/* ul rule needed to reset style for sub-bullets */
	</style>
</head>
<body>

<!-- Header -->
<div class='header'>
	[ <a href='./Pharmacognosy.html'>Prev</a> ]

	[ <span class='insen'>Index</span> ]

	[ <a href='..\Home.html'>Next</a> ]
</div>

<hr />

<!-- Wiki content -->

<div class='pages'>
	<div class='heading'>
	<h1>Pharmacology <a name='26:Pharmacology'></a></h1>
	</div>

	<div class='content'>
	<p>
<img src="./Pharmacology/pasted_image.png">
</p>
<h1>OVERVIEW</h1>

<p>
→ Anxiety is an unpleasant state of tension,apprehension or uneasiness.<br>
<ul style='padding-left: 30pt'>
<li>a mental distrurbances</li>
</ul>
→ physical symptoms<br>
<ul style='padding-left: 30pt'>
<li>tachycardia</li>
<li>sweating</li>
<li>trembling </li>
<li>palpitation
<ul>
<li>invole sympathetic activation</li>
</ul></li>
</ul>
→ Debilitating anxiety may be treated<br>
<ul style='padding-left: 30pt'>
<li>anti-anxiety drugs</li>
<li>behavioral therapy</li>
<li>psychotherapy</li>
</ul>
</p>

<h1>BENZODIAZEPINES</h1>

<p>
→ most widely used anxiolytic drugs.<br>
→ prelaced barbiturates and <i>meprobamate</i>
</p>

<p>
A.MECHANISM OF ACTION<br>
→ target of benzodiazepines action<br>
<ul style='padding-left: 30pt'>
<li>GABAa receptors
<ul>
<li>GABA is the major inhibitory neurotransmitter in the CNS.</li>
</ul></li>
</ul>
→ receptros composed primarly by<br>
<ul style='padding-left: 30pt'>
<li>α,β and γ subunit families</li>
</ul>
→ depending on types , number of subunits , brain region site , <br>
<ul style='padding-left: 30pt'>
<li>result in different pharmacological effects</li>
</ul>
→ Benzo's<br>
<ul style='padding-left: 30pt'>
<li>modulates GABA effects by 
<ul>
<li>binding to a specific, high affinity at 
<ul>
<li>αsubunit and γ2subunit</li>
</ul></li>
</ul></li>
</ul>
→ in the CNS commonly found<br>
<ul style='padding-left: 30pt'>
<li>[BZ1] α1-subunit ,[BZ2] α2-subunit</li>
</ul>
→ benzodiazepines receptors on CNS are paraller those of the GABA neurons.<br>
→ by binding cauasing<br>
<ul style='padding-left: 30pt'>
<li>Chloride-channel to open
<ul>
<li>↑ chloride conductance</li>
</ul></li>
</ul>
→ Benzodiazepines ↑ the frequency of channel opening.<br>
→ influx of chloride<br>
<ul style='padding-left: 30pt'>
<li>small hyperpolarization</li>
<li>moves postsynaptic potential away</li>
<li>inhibit the formation of action potential</li>
</ul>
B.ACTIONS<br>
<ol type="1" start="1">
<li>Reduction of anxiety:
<ul>
<li>at low doses are anxiolytic
<ul>
<li>by selectively enhancing GABAergic transmission  have α2subunit
<ul>
<li>or by inhibiting neuronal circuits in the limbic system of the brain.</li>
</ul></li>
</ul></li>
</ul></li>
</ol>
2.Sedative and hypnotic actions:<br>
<ul style='padding-left: 30pt'>
<li>at higher doses artificially produce sleep</li>
<li>effects mediated by α1-GABAa-receptors</li>
</ul>
3.Anterograde amnesia:<br>
<ul style='padding-left: 30pt'>
<li>mediated by α1-GABAa receptors</li>
<li>impairs learning and form of new memories.</li>
</ul>
4.Anticonvulsant:<br>
<ul style='padding-left: 30pt'>
<li>several benzo's have this activity and used for epilepsy and other seizure disorders</li>
<li>partially mediated by a1-GABAa-receptors</li>
</ul>
5.Muscle relaxant<br>
<ul style='padding-left: 30pt'>
<li>at high doses rexal spasticity of skeleta muscle
<ul>
<li>↑ presynaptic inhibition in the spinal chord</li>
</ul></li>
</ul>
</p>

<h1>Theurapeutic uses</h1>

<p>
<ol type="1" start="1">
<li>Anxiety disorders
<ul>
<li>secondary to panic disorder</li>
<li>GAD </li>
<li>social anxiety disorder</li>
<li>extreme anxiety</li>
</ul></li>
</ol>
→ should not be used to alleviate the normal stress<br>
→ reserved for continued time because the addiction potentnial<br>
→ <i>Clonazepam,lorazepam,diazepam </i>[long-acting agents]<br>
<ul style='padding-left: 30pt'>
<li>prolonged period of time treatment</li>
</ul>
→ for panic disorders<br>
<ul style='padding-left: 30pt'>
<li><i>Alprazolam </i>
<ul>
<li>is effective short and long term treatment</li>
</ul></li>
</ul>
2.Muscular disorders<br>
→ <i>Diazepam</i><br>
<ul style='padding-left: 30pt'>
<li>skeletal muscsle spams	
<ul>
<li>from degenerative disorders 
<ul>
<li>multiple sclerosis and cerebral palsy</li>
</ul></li>
</ul></li>
</ul>
3.Seizures<br>
→ <i>Clonazepam</i><br>
<ul style='padding-left: 30pt'>
<li>epilepsy </li>
</ul>
→ <i>Diazepam,lorazepam</i><br>
<ul style='padding-left: 30pt'>
<li>grand mal epileptic seizures</li>
<li>status epilepticus</li>
</ul>
→ <i>Chlordiazepoxide,clorazepate,diazepam,oxazepam</i><br>
<ul style='padding-left: 30pt'>
<li>acute treatment of alcochol withdrawal</li>
</ul>
4.Sleep disorders<br>
→ not all benzo's are useful as hypnotic agents<br>
<ul style='padding-left: 30pt'>
<li>although all have sedative or calming effects</li>
</ul>
→ ↓ latency to sleep onest<br>
<ul style='padding-left: 30pt'>
<li>↑ nonrapid eye movement
<ul>
<li>REM sleep and slow-wave sleep ↓</li>
</ul></li>
</ul>
→ commonly prescribed benzo's for sleep disorders<br>
<ul style='padding-left: 30pt'>
<li><i>flurazepam</i></li>
<li><i>temazepam [intermediate-acting]</i></li>
<li><i>triazolam [short-acting]</i></li>
</ul>
</p>

<h1>FLURAZEPAM</h1>

<p>
→ long acting benzo<br>
<ul style='padding-left: 30pt'>
<li>↓ sleep-induction and the number of awakenings </li>
<li>↑ duration of sleep</li>
</ul>
→ the long-term effect cause<br>
<ul style='padding-left: 30pt'>
<li>litlte rebound insomnia.</li>
</ul>
→ maintain effectiveness for up to 4 weeks<br>
→ parent drug and active metabolites<br>
<ul style='padding-left: 30pt'>
<li>half life : 85 hours
<ul>
<li>which may result daytime sedation and accumulation of the drug</li>
</ul></li>
</ul>
</p>

<h1>TEMAZEPAM</h1>

<p>
→ for patients experiance frequent wakening<br>
→ peak sedative effect 1 to 3 hours<br>
<ul style='padding-left: 30pt'>
<li>oral dose </li>
<li>1-2 hours before the desired bedtime</li>
</ul>
</p>

<h1>TRIAZOLAM</h1>

<p>
→ relatively short duration of action<br>
<ul style='padding-left: 30pt'>
<li>induce sleep in patients with insomnia</li>
</ul>
→ tolerance frequently develops within a few days<br>
<ul style='padding-left: 30pt'>
<li>rebound insomnia</li>
</ul>
→ intemittently rather than daily<br>
→ to be given less than 2 to 4 weeks
</p>

<h1>PHARMACOKINETICS</h1>

<p>
1.Absorption and distribution<br>
→ benzo's are lipophilic<br>
→ rapidly and completely absorbed after oral admin.<br>
→ and well distributed throughout the body
</p>

<p>
2.Duration of action<br>
→ half lives are very important clinically<br>
<ul style='padding-left: 30pt'>
<li>determine therapeutic usefulness.</li>
</ul>
→ divided into<br>
<ul style='padding-left: 30pt'>
<li>short - , intermediate- , long-acting groups </li>
<li><img src="./Pharmacology/pasted_image001.png"></li>
</ul>
3.FATE<br>
→ metabolized by the hepatic microsomal system to compounds that are also active<br>
→ drug effects are terminated not only from the excrection but also from the redistribution<br>
<ul style='padding-left: 30pt'>
<li>excreted in urine as glucoronides or oxidezed metabolites.</li>
</ul>
→ all corss the placenta barrier
</p>

<h1>Dependence</h1>

<p>
→ psychological and physical dependence  can develop <br>
<ul style='padding-left: 30pt'>
<li>if high doses are given for prolonged period of time</li>
</ul>
→ abrupt discontinuation → withdrawal symptoms<br>
<ul style='padding-left: 30pt'>
<li>confusion,anxiety,agitation,restelness, and other</li>
</ul>
</p>

<h1>Adverse effects</h1>

<p>
1.Drowsiness and confusion<br>
<ul style='padding-left: 30pt'>
<li>most common</li>
<li>ataxia in higher doses</li>
</ul>
→ Precautions<br>
<ul style='padding-left: 30pt'>
<li>in patients with liver disease</li>
<li>alcochola and CNS depressants enhance sedative-hypnotic effect</li>
</ul>
<img src="./Pharmacology/pasted_image002.png">
</p>

<h1>BENZODIAZEPINE ANTAGONIST</h1>

<p>
→ <i>Flumazenil </i><br>
<ul style='padding-left: 30pt'>
<li>GABA-receptor antagonist
<ul>
<li>which can rapidly reverse the effects of benzodiazepines</li>
</ul></li>
</ul>
→ IV admin. only<br>
→ half life : 1hour<br>
→ maintain reversal of a long-acting benzo<br>
→ may percipitate withdrawal<br>
<ul style='padding-left: 30pt'>
<li>can cause seizure</li>
<li>dizziness</li>
<li>nausea</li>
<li>vomiting</li>
<li>agitation are the most common side effects</li>
</ul>
</p>

<h1>OTHER ANXIOLYTIC AGENTS</h1>

<br>

<p>
<ol type="a" start="1">
<li>ANTIDEPRESSANT</li>
</ol>
→ efficacy on <br>
<ul style='padding-left: 30pt'>
<li>long-term symptoms of chronic anxiety disorders</li>
<li>should be consider as first-line agent
<ul>
<li>especially in patients which are addicted to other substances</li>
</ul></li>
</ul>
→ SSRIs[selective-serotonine-reuptake-inhibitors]<br>
<ul style='padding-left: 30pt'>
<li><i>Escitalopram</i></li>
</ul>
<ul>
<li>or</li>
</ul>
→ SNRI's[selective-serotonin-nonepinephrine-reuptake-inhibitors]<br>
<ul style='padding-left: 30pt'>
<li><i>Venlafaxine</i></li>
<li>may be used alone</li>
<li>or in combo with low dose benzo for the first week of treatment</li>
</ul>
→ SSRIS AND SNRI have lower potential for physical dependence<br>
→ longer-term of combo often requried to maintain<br>
<ul style='padding-left: 30pt'>
<li>ongoing benifit and prevent relapse</li>
<li>after 4-6 weeks benzo's doses can be tappered</li>
</ul>
</p>

<p>
b.BUSPIRONE<br>
→ chronic treatmnet of GAD<br>
<ul style='padding-left: 30pt'>
<li>efficay comperable to that of benzos</li>
</ul>
→ is not effective against short term treatment of actute anxiety states<br>
→ mediated by serotonin 5-HT1 receprtors<br>
→ in addition to benzo's<br>
<ul style='padding-left: 30pt'>
<li>lack anticonvulsant and muscle-relaxant activity</li>
<li>cause little sedation</li>
</ul>
→ can cause :<br>
<ul style='padding-left: 30pt'>
<li>hypothermia</li>
<li>↑ growth hormone and prolactine</li>
<li>headaches</li>
<li>dizznes</li>
<li>nervousness</li>
</ul>
→ does not potentiate the CNS depression of alochol.
</p>

<h1>BARBITURATES</h1>

<p>
→ mainstay of treatment to sedate patients<br>
<ul style='padding-left: 30pt'>
<li>induce/maintain sleep</li>
</ul>
→ replaced by benzodiazepines because<br>
<ul style='padding-left: 30pt'>
<li>induce tolerance</li>
<li>drug-metabolizing enzymes</li>
<li>physical dependance.</li>
</ul>
→ can block glutamate receptros<br>
→ anesthetic conc. of penpbarbital also block high-frequency sodium channels<br>
<ul style='padding-left: 30pt'>
<li>↓ neuronal activity</li>
</ul>
ACTIONS<br>
→ <i>THIOPENTAL</i><br>
<ul style='padding-left: 30pt'>
<li>act within seconds</li>
<li>duration of action 30 minutes
<ul>
<li>I.V induction  of anesthesia</li>
</ul></li>
</ul>
→ <i>PHENOBARBITAL</i><br>
<ul style='padding-left: 30pt'>
<li>duration of action greater than a day</li>
</ul>
</p>


	</div>

	<br />

	<div class='page-footer'>

			<b>Attachments:</b>
			<table>

			<tr><td><a href='./Pharmacology/pasted_image.png'>pasted_image.png</a></td><td>&nbsp;</td><td>74.4kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image001.png'>pasted_image001.png</a></td><td>&nbsp;</td><td>46.7kb</td></tr>


			<tr><td><a href='./Pharmacology/pasted_image002.png'>pasted_image002.png</a></td><td>&nbsp;</td><td>32.7kb</td></tr>

			</table>
	</div>

	

</div>

</body>
</html>
